Open AccessAssessing Bone Marrow Activity with [18F]FLT PET in Patients with Essential Thrombocythemia and Prefibrotic Myelofibrosis: A Proof of Concept
Author(s) -
Mohamed A Yassin,
Sadek Nehmeh,
Abdulqadir J. Nashwan,
Samah Kohla,
Shehab Mohamed,
Omar M Ismail,
Ahmad Al Sabbagh,
Dina Sameh Soliman,
Lajos Szabados,
Hadi Fayad
Publication year - 2022
Publication title -
technology in cancer research and treatment
Language(s) - English
Resource type - Journals
eISSN - 1533-0346
pISSN - 1533-0338
DOI - 10.1177/15330338221086396
Subject(s) - medicine , myelofibrosis , bone marrow , essential thrombocythemia , nuclear medicine , gold standard (test) , standardized uptake value , positron emission tomography , radiology , polycythemia vera
Objectives: This study aims to assess the value of FLT-PET as a non-invasive tool to differentiate between patients with ET and Pre-PMF. This study is a pilot study to have a proof of concept only. Methods: This is a prospective, interventional study where a total of 12 patients were included. Each patient underwent FLT PET imaging as well as bone marrow examination (gold standard). In addition, semi-quantitative (SUVmax and SUVmean) measurements of FLT uptake in the liver, spleen, and Lspine, SUVmean, as well as the Total Lesion Glycolysis (TLG) of the Lspine were performed. Results from the two patient cohorts were compared using = Kruskal-Wallis statistical test. A P-value of .05). In contrast, TLG measurements in the LSpine were statistically different ( P = .013), and therefore, compared to gold standard bone marrow results, TLG can separate ET and Pre-PMF patients. Conclusion: This study is a proof of concept about the potential to discriminate between ET and pre-PMF patients in a non-invasive way. TLG of the LSpine in FLT PET images is a potential quantitative parameter to distinguish between ET and pre-PMF patients.